AU2022242840A1 - Methods kits and compositions for characterizing an anti-inflammatory response of a product - Google Patents
Methods kits and compositions for characterizing an anti-inflammatory response of a product Download PDFInfo
- Publication number
- AU2022242840A1 AU2022242840A1 AU2022242840A AU2022242840A AU2022242840A1 AU 2022242840 A1 AU2022242840 A1 AU 2022242840A1 AU 2022242840 A AU2022242840 A AU 2022242840A AU 2022242840 A AU2022242840 A AU 2022242840A AU 2022242840 A1 AU2022242840 A1 AU 2022242840A1
- Authority
- AU
- Australia
- Prior art keywords
- product
- tnf
- value
- inflammatory
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 155
- 239000000203 mixture Substances 0.000 title abstract description 34
- 230000031990 negative regulation of inflammatory response Effects 0.000 title abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 154
- 210000004027 cell Anatomy 0.000 claims description 322
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 294
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 292
- 239000003636 conditioned culture medium Substances 0.000 claims description 238
- 238000004519 manufacturing process Methods 0.000 claims description 165
- 238000012360 testing method Methods 0.000 claims description 161
- 230000000694 effects Effects 0.000 claims description 146
- 230000003213 activating effect Effects 0.000 claims description 112
- 230000000770 proinflammatory effect Effects 0.000 claims description 111
- 210000001519 tissue Anatomy 0.000 claims description 99
- 102000004127 Cytokines Human genes 0.000 claims description 85
- 108090000695 Cytokines Proteins 0.000 claims description 85
- 239000000126 substance Substances 0.000 claims description 81
- 210000001691 amnion Anatomy 0.000 claims description 44
- 239000001963 growth medium Substances 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 210000002437 synoviocyte Anatomy 0.000 claims description 30
- 102000004889 Interleukin-6 Human genes 0.000 claims description 29
- 108090001005 Interleukin-6 Proteins 0.000 claims description 29
- 210000000988 bone and bone Anatomy 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 12
- 102000013691 Interleukin-17 Human genes 0.000 claims description 11
- 108050003558 Interleukin-17 Proteins 0.000 claims description 11
- 108090001007 Interleukin-8 Proteins 0.000 claims description 11
- 102000004890 Interleukin-8 Human genes 0.000 claims description 11
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 11
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 11
- 102000004140 Oncostatin M Human genes 0.000 claims description 11
- 108090000630 Oncostatin M Proteins 0.000 claims description 11
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims description 10
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 10
- 102000003814 Interleukin-10 Human genes 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 102000003815 Interleukin-11 Human genes 0.000 claims description 10
- 108090000177 Interleukin-11 Proteins 0.000 claims description 10
- 102000003810 Interleukin-18 Human genes 0.000 claims description 10
- 108090000171 Interleukin-18 Proteins 0.000 claims description 10
- 108090000978 Interleukin-4 Proteins 0.000 claims description 10
- 102000004388 Interleukin-4 Human genes 0.000 claims description 10
- 102000003816 Interleukin-13 Human genes 0.000 claims description 9
- 108090000176 Interleukin-13 Proteins 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 230000000921 morphogenic effect Effects 0.000 claims description 9
- 210000002536 stromal cell Anatomy 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 230000002608 insulinlike Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 19
- 239000000047 product Substances 0.000 description 438
- 238000011282 treatment Methods 0.000 description 88
- 230000007423 decrease Effects 0.000 description 60
- 238000003556 assay Methods 0.000 description 58
- 238000002965 ELISA Methods 0.000 description 37
- 230000009467 reduction Effects 0.000 description 30
- 230000004054 inflammatory process Effects 0.000 description 29
- 206010061218 Inflammation Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 230000028709 inflammatory response Effects 0.000 description 27
- 239000003102 growth factor Substances 0.000 description 25
- 230000002757 inflammatory effect Effects 0.000 description 25
- 201000008482 osteoarthritis Diseases 0.000 description 23
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 22
- 239000012091 fetal bovine serum Substances 0.000 description 22
- 239000006228 supernatant Substances 0.000 description 22
- 230000003247 decreasing effect Effects 0.000 description 20
- 208000012659 Joint disease Diseases 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 239000000463 material Substances 0.000 description 16
- 102100027995 Collagenase 3 Human genes 0.000 description 15
- 108050005238 Collagenase 3 Proteins 0.000 description 15
- 102000035195 Peptidases Human genes 0.000 description 15
- 108091005804 Peptidases Proteins 0.000 description 15
- 239000004365 Protease Substances 0.000 description 15
- 238000011201 multiple comparisons test Methods 0.000 description 15
- 230000037452 priming Effects 0.000 description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 description 15
- 230000005305 organ development Effects 0.000 description 14
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 101710115248 Arylsulfatase A Proteins 0.000 description 12
- 102100022146 Arylsulfatase A Human genes 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 229920002877 acrylic styrene acrylonitrile Polymers 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 8
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 8
- 102000015696 Interleukins Human genes 0.000 description 8
- 108010063738 Interleukins Proteins 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 210000000845 cartilage Anatomy 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 8
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 7
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 7
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 7
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 102100030416 Stromelysin-1 Human genes 0.000 description 7
- 101710108790 Stromelysin-1 Proteins 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000003828 downregulation Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 6
- 229940126864 fibroblast growth factor Drugs 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 101000901140 Homo sapiens Arylsulfatase A Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000012911 assay medium Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 239000012737 fresh medium Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000007310 pathophysiology Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- -1 IL- lra Proteins 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010042863 synovial sarcoma Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000055008 Matrilin Proteins Human genes 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 2
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000005067 joint tissue Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 210000005152 placental membrane Anatomy 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000012966 Growth Differentiation Factor 5 Human genes 0.000 description 1
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010003059 aggrecanase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
- 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000003530 single readout Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
- C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164846P | 2021-03-23 | 2021-03-23 | |
| US63/164,846 | 2021-03-23 | ||
| US17/215,921 | 2021-03-29 | ||
| US17/215,921 US20210311022A1 (en) | 2020-03-27 | 2021-03-29 | Methods, kits and compositions for characterizing an anti-inflammatory response of a product |
| PCT/US2022/021614 WO2022204330A1 (en) | 2021-03-23 | 2022-03-23 | Methods kits and compositions for characterizing an anti-inflammatory response of a product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022242840A1 true AU2022242840A1 (en) | 2023-09-28 |
Family
ID=83396068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022242840A Pending AU2022242840A1 (en) | 2021-03-23 | 2022-03-23 | Methods kits and compositions for characterizing an anti-inflammatory response of a product |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4312597A1 (he) |
| JP (1) | JP2024512060A (he) |
| AU (1) | AU2022242840A1 (he) |
| CA (1) | CA3213824A1 (he) |
| IL (1) | IL305969A (he) |
| WO (1) | WO2022204330A1 (he) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050261239A1 (en) * | 2004-05-23 | 2005-11-24 | Universiteit Van Maastricht | Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue |
| CN102811736B (zh) * | 2009-11-30 | 2016-01-20 | 生物测试股份公司 | 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体 |
| US8834928B1 (en) * | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
-
2022
- 2022-03-23 AU AU2022242840A patent/AU2022242840A1/en active Pending
- 2022-03-23 JP JP2023558703A patent/JP2024512060A/ja active Pending
- 2022-03-23 IL IL305969A patent/IL305969A/he unknown
- 2022-03-23 WO PCT/US2022/021614 patent/WO2022204330A1/en active Application Filing
- 2022-03-23 CA CA3213824A patent/CA3213824A1/en active Pending
- 2022-03-23 EP EP22776604.5A patent/EP4312597A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024512060A (ja) | 2024-03-18 |
| EP4312597A1 (en) | 2024-02-07 |
| CA3213824A1 (en) | 2022-09-29 |
| WO2022204330A1 (en) | 2022-09-29 |
| IL305969A (he) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miyanishi et al. | Dose-and time-dependent effects of cyclic hydrostatic pressure on transforming growth factor-β3-induced chondrogenesis by adult human mesenchymal stem cells in vitro | |
| Kondo et al. | Contribution of the interleukin‐6/STAT‐3 signaling pathway to chondrogenic differentiation of human mesenchymal stem cells | |
| Jimbo et al. | Positive feedback loop of interleukin-1β upregulating production of inflammatory mediators in human intervertebral disc cells in vitro | |
| Janicki et al. | Prediction of in vivo bone forming potency of bone marrow-derived human mesenchymal stem cells | |
| JP6921249B2 (ja) | 向上された臍帯由来付着型幹細胞、その製造方法及びその用途 | |
| Han et al. | Metformin decreases LPS-induced inflammatory response in rabbit annulus fibrosus stem/progenitor cells by blocking HMGB1 release | |
| Li et al. | The action of resveratrol, a phytoestrogen found in grapes, on the intervertebral disc | |
| Li et al. | Characteristics and potentials of stem cells derived from human degenerated nucleus pulposus: potential for regeneration of the intervertebral disc | |
| Li et al. | Preclinical ex-vivo testing of anti-inflammatory drugs in a bovine intervertebral degenerative disc model | |
| Liu et al. | Inhibition of titanium particle-induced osteoclastogenesis through inactivation of NFATc1 by VIVIT peptide | |
| Lian et al. | Collagen type II is downregulated in the degenerative nucleus pulposus and contributes to the degeneration and apoptosis of human nucleus pulposus cells | |
| Sun et al. | The changes in the expression of NF-KB in a degenerative human intervertebral disc model | |
| Esa et al. | Extracellular vesicles in the synovial joint: is there a role in the pathophysiology of osteoarthritis? | |
| Akamine et al. | Prolonged matrix metalloproteinase-3 high expression after cyclic compressive load on human synovial cells in three-dimensional cultured tissue | |
| Cai et al. | The paracrine effect of degenerated disc cells on healthy human nucleus pulposus cells is mediated by MAPK and NF-κB pathways and can be reduced by TGF-β1 | |
| Buse et al. | CELLULAR AND MOLECULAR ACTIVITY OF A STANDARDIZED SMALL SEA FISH EXTRACT IN AN EXPERIMENTAL MODEL OF PRIMARY HUMAN CARTILAGE CELLS. | |
| Li et al. | M2 macrophage‐conditioned medium inhibits intervertebral disc degeneration in a tumor necrosis factor‐α‐rich environment | |
| Qu et al. | FSTL1 promotes inflammatory reaction and cartilage catabolism through interplay with NFκB signaling pathways in an in vitro ONFH model | |
| Qu et al. | M1 macrophage-derived Interleukin-6 promotes the osteogenic differentiation of ligamentum flavum cells | |
| Gong et al. | LncRNA PRNCR1 regulates CXCR4 expression to affect osteogenic differentiation and contribute to osteolysis after hip replacement | |
| Gong et al. | Bone morphogenetic protein-7 retards cell subculture-induced senescence of human nucleus pulposus cells through activating the PI3K/Akt pathway | |
| Xu et al. | FSTL1 promotes nitric oxide-induced chondrocyte apoptosis via activating the SAPK/JNK/caspase3 signaling pathway | |
| Ying et al. | Stromal cell-derived factor-1α promotes recruitment and differentiation of nucleus pulposus-derived stem cells | |
| Zhao et al. | Nucleus pulposus cell senescence is regulated by substrate stiffness and is alleviated by LOX possibly through the integrin β1-p38 MAPK signaling pathway | |
| Heggli et al. | Pro-fibrotic phenotype of bone marrow stromal cells in Modic type 1 changes |